• 作者：Simon Fishel^a ; Deborah Baker^b ; ^{d.baker@ihgpharmaco.com" class="auth_mail" title="E-mail the corresponding author} ; Janine Elson^a ; Maha Ragunath^c ; Glenn Atkinson^d ; Adel Shaker^e ; Ahmed Omar^f ; Rahnuma Kazem^g ; Ashley Beccles^a ; Ian A. Greer^h
• 关键词：PMPC ; IVF ; ANXA5 M2 ; LMWH ; Live birth
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：10
• 期：Complete
• 页码：298-304
• 全文大小：248 K

•

The ANXA5 M2 haplotype is associated with early recurrent pregnancy loss and PMPC and is common in IVF populations.

•

Screening couples and treating with LMWH after IVF achieved a similar live birth outcome to younger more fertile couples.

•

Outcome results indicate benefit of screening and treatment with LMWH, supporting further studies on the role of M2 in PMPC.

Pregnancy failure, miscarriage and placental complications affect over 25% of pregnancies. No biomarker exists for treatment with anticoagulants. A novel marker for risk of these has been identified with a reduction in the naturally occurring placental anticoagulant required for normal development of the placenta and pregnancy. It is transmitted equally by the male and female to the embryo. This IVF study of infertile couples has shown that by testing them and treating the female of positive couples with anticoagulant from time of embryo transfer the live birth outcome was similar to that of younger less infertile couples.